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LIPID PROFILE IN PREGNANCY INDUCED HYPERTENSION  
 
 
INTRODUCTION 
 
 Comprehensive  antenatal  care  should  ensure  a  healthy  pregnancy  with 
an  outcome  of  a  healthy  mother and a healthy fetus with a good birth weight. 
Birth weight is not only the indicator of the health of the new born child but also it 
predicts the future health of the child. Low birth weight child is prone to suffer 
from diabetes, hypertension, and coronary vascular disorders in their later life. 1  
 
 Pre eclampsia, a disease of pregnant women is one of the leading causes of 
maternal and fetal morbidity and mortality2 and it occurs in 2-7% of all 
pregnancies. 3 
 
 The incidence of pregnancy induced hypertension in India ranges from 5-
15% 
 
 In Primi’s - 16% 
 In Multi’s- 7% 
 
 It causes IUGR leading to low birth weights.1,5 It increases maternal 
mortality by 10-15% and perinatal mortality and morbidity by 15 to 25%1. 
 
 With high blood pressure, there is an increase in the vascular resistance 
which may hinder blood flow in different organ systems in the expectant mother 
including liver, kidneys, brain, uterus and placenta 3, 4 
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Complications of PIH are  
 
1. HELLP syndrome7- which includes Hemolysis, elevated liver 
enzymes, low platelets leading to acute fatty liver and liver rupture.  
2. Renal failure / Impairment 
3. Pulmonary edema 
4. Disseminated intravascular coagulation 
5. Eclampsia  
6. Placental abruption  
 
 Early identification of women at risk for PIH may help in preventing  the 
complications of the disease.  
 
 According to the norms of American college of obstetrics and 
Gynaecologist, PIH6 is defined as  
 
1. Systolic Blood Pressure > 140mmHg 
2. Diastolic Blood Pressure > 90mmHg 
3. Increase of > 30mgHg in systolic pressure 
4. Increase of > 15mmHg in diastolic Blood Pressure 5 
 
 in a previously normotensive woman. 
 
 If proteinuria develops along with increased Blood pressure, then it comes 
under pre eclampsia.  
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Pathophysiology of PIH: 
 
 The most important determinants of blood pressure are1 
 1. Cardiac output 
 2. Peripheral vascular resistance 
 
 Even when cardiac output is increased7 during normal pregnancy there is a 
relative decrease in blood pressure due to the decrease in peripheral vascular 
resistance.  But in PIH there is increased resistance which is brought about by 
 
 1. Increased response to vasopressors8.  
 
2. Altered lipid synthesis leading to decrease in the ratio of  
PGI2/TXA2 and antioxidants/lipid peroxidases8,17. Balance  between 
peroxide  generating and peroxide removing mechanisms may 
control the rate of generation of prostaglandins. Prostacyclin, a 
potent vasodilator and antiaggregatory agent is synthesised in 
vascular endothelium.  This is balanced by thromboxane, a potent 
locally acting vasoconstrictor and proaggregatory agent. Lipid 
peroxides inhibit prostacyclin synthase but do not influence 
thromboxane synthase55,65. leading to  decrease in vasodilator effect.  
Inhibition of prostacyclin synthesis leads to the formation of foam 
cells and so atherogenesis. Acute atherosis, including the presence of 
foam cells is a feature of placental bed biopsy specimens from 
women with pre-eclampria74.   
  
3. Changes in the local factors like NO, endothelins.  
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 There  is  an  accumulated  evidence  stating  that  abnormal  placentation  is 
one of  the  initial  events  leading  to  this  disease.  The  main  feature  is 
inadequate  trophoblastic  invasion of maternal spiral arterioles2,3,7,9 and the 
arteries  retain  their  musculoelastic  walls and thus respond to the 
vasoconstrictors  produced (Eg.)  leukotrienes,  lipid peroxidases. 
 
Factors  involved  in  abnormal  placentation  are : 
Intrinsic  factors  acting  in  concert  with  external  extrinsic  maternal  
uterine factors.  
 
Intrinsic factors  abnormal biology of extra villous trophoblasts. 
 
                      Invasive extra villous trophoblasts in normal pregnancy. 
 
 
 
  
 
Interstitial trophoblasts invading                              Endovascular cytotrophoblasts 
Decidual stroma reaching myometrium     
 
 
At the end form multi nuclear giant cells                  invade the lumen of uterine  
                                                                                   Spiral arterioles 
 
 
Release vasodilators (No)                                           anchor to the vessel wall 
                                                                                                                
 
Act on spiral arteries before destruction                    promote arteriolar dilation 
by endovascular trophoblasts 
 
                                                                                 High caliber capacitance vessels 
 
  
                                                                                 Adequate perfusion of   
                                                                                   Fetoplacental unit    
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In  pre-eclampsia : 
 
Impaired  interstitial  trophoblasts  invasion  and  failure  of  vascular 
  
Invasion narrow  bore  high  resistance  spiral  arterioles       inadequate 
 
 Perfusion  of  fetoplacental  unit.  
 
Extrinsic  uterine  maternal  factors  are : 
1.  Impaired  decidual  remodelling2,9  
2.  Impaired function of uterine natural killer cells. Interaction of 
inhibitory  killer  cell  immunoglobulin  receptors  or  uterine  natural  
killer  cells with  trophoblastic  human  leukocyte  Antigen  C  leads  
to  excessive  inhibition of  uterine  natural  killer  cell  activity  and  
so  decreased  invasion  of trophoblasts  leading to defective 
trophoblast remodeling of maternal blood vessels. 
3.  Maternal  endothelial   failure  to  express  adhesion  molecules.  
(i.e.) impairment  in  transformation  of  epithelial  tissue  to  
endothelium as  in  normal  pregnancy.  
 
Biochemical  aspects  of  placental  Ischaemia2   
 
1. Binding  of  vascular  endothelial  growth  factor  and  placental  growth  
factor to the Fms-like tyrosine kinase 1 receptor on cytotrophoblasts 
stimulates production of nitric oxide by endothelial nitric oxide synthase. 
Interaction of vascular endothelial growth factor and placental growth factor 
with the Fms-like tyrosine kinase 1 receptor is inhibited by soluble Fms-like 
tyrosine kinase 1. Normal  placenta  with  sufficient  tissue  L-arginine  
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sustains  adequate  generation  of  nitric oxide  by  endothelial  nitric oxide  
synthase (left panel). 
 
2. By contrast, in pre-eclampsia, increased levels of soluble Fms-like tyrosine 
kinase1 inhibit activation of endothelial nitric oxide synthase, by the Fms-
like tyrosine kinase 1 receptor. At the same time, excessive arginase II 
expression reduces the placental L-arginine concentration, causing 
endothelial nitric oxide synthase  to  preferentially  facilitate  superoxide  
anion  production. Superoxide anion  reacts  with  nitric oxide  to  form  
peroxynitrite,  thus  reducing  the  half-life  of  nitric oxide (right panel). 
This  promotes  abnormal  placental  perfusion and  microvascular  
oxidative  damage. 
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eNOS, endothelial nitricoxide synthase; Flt1, Fms-like tyrosine kinase 1; L-Arg, L-
arginine; NO, nitric oxide; O2–, superoxideanion; ONOO–, peroxynitrite; PlGF, 
placental growth factor; sFlt1, soluble Fms-like tyrosine kinase 1; 
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MATERNAL LEVEL 
 
The placental abnormalities described, have several maternal consequences. 
 
2 Stages of Pre – Eclampsia2  
Stage 1 
 
 
Defective  placental  implantation  
 
 
Placental  Ischemia  
 
 
 
 
  Placental factors     Systemic hemodynamic  
 adaptation  
 
 
 
 
Stage 2      Endothelial  dysfunction 
 
 
                  Reduced  perfusion  of  affected  organs  
                 (Predominantly kidneys, liver & brain) 
 
 
              Clinical manifestation of PE 
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Reduced uterine perfusion pressure 
 
increased maternal plasma & placental sflt -1 
 
                                             decreased Plasma VEGF, PlGF 
 
Endothelial Dysfunction 
 
increased ET-1 & ROS,  ↓ NO             
                                                                                                  
 
 increased Total peripheral resistance   decreased RBF & GFR 
 
          Decreased Renal excretory function 
 
 
Hypertension  
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Role of the soluble form of Fms-like tyrosine kinase 1 in the maternal 
syndrome of pre-eclampsia 
 
Most  of  the  Fms-like tyrosine kinase 1 produced  by  human   placenta  is  a 
soluble  form  generated  by  alternative  splicing . Soluble Fms-like tyrosine 
kinase 1 is  released  in  large  amounts  into  the  blood. Soluble  Fms-like tyrosine 
kinase 1 binds  both vascular  endothelial growth factor and placental growth 
factor,  reducing  their  free  levels  in  the  blood  by  working  as  a  soluble 
antagonist  of both factors, and maintaining normal endothelial function of 
maternal vasculature (left panel). Pre-eclamptic placenta releases higher amounts 
of soluble Fms-like tyrosine kinase 1 than normal placenta (right panel),depriving 
the vasculature of kidney, liver, brain and other organs of essential maintenance 
signals, thereby triggering the maternal vascular dysfunction of pre-eclampsia.  
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PlGF, placental growth factor;sFlt1, soluble Fms-like tyrosine kinase 1; 
VEGF, vascular endothelial growth factor. 
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Unifying hypothesis of pre-eclampsia pathophysiology.  
 
According to this, pre-eclampsia is a disease of placentation triggered by 
reduced activity or half-life of nitric oxide secondary to low placental L-arginine 
concentration, which is in turn related to excessive arginase II expression. Low L-
arginine levels stimulate endothelial nitric oxide synthase to generate reactive 
oxygen species (e.g. peroxynitrite and hydroxyl radical) and locally exacerbate 
oxidative stress. Reduced flow through the placental L-arginine–nitric oxide 
pathway is also consistent with the higher resistance and hypoperfusion of the 
fetal–placental circulation. In response to the restricted placental blood flow and 
consequent hypoxia, the placenta releases into the maternal circulation a number of 
factors including soluble Fms-like tyrosine kinase 1 and reactive oxygen species, 
which initiate the vascular dysfunction characteristic of the maternal syndrome. 
 
Soluble Fms-like tyrosine kinase 1 is present at high concentrations in the 
blood of pre-eclamptic women,and administration of soluble Fms-like tyrosine 
kinase 1 to animals produces a maternal syndrome resembling that of pre-
eclampsia.  
 
In a further attempt to ameliorate perfusion of the placenta as well as of the 
maternal organs involved in pre-eclampsia, upregulation of the B2 receptor for the 
vasodilator bradykinin occurs. The B2 receptors heterodimerize with the 
angiotensin II type 1 receptor, thereby increasing vascular and inflammatory 
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responsiveness to angiotensin II, paradoxically reducing systemic organ perfusion 
and promoting generation of reactive oxygen species. 
 
 Concomitant production of agonist angiotensin II type 1 receptor 
autoantibodies also contributes to oxidative stress. A positive-feedback loop is 
initiated that eventually results in the full-blown clinical syndrome of pre-
eclampsia. 
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Ang II, angiotensin II; AT1, angiotensin II type 1 receptor; eNOS, endothelial 
nitric oxide synthase; 
L-Arg, L-arginine; MMP2, matrix metalloproteinase 2; MMP9, matrix 
metalloproteinase 9; NO, nitric oxide; 
O2–, superoxide anion; OH•, hydroxyl radical; PGI2, prostacyclin; sFlt1, soluble 
Fms-like tyrosine kinase 1; 
TxA2, thromboxane A2; VEGF, vascular endothelial growth factor 
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Lipid metabolism in pregnancy  
Normal pregnancy is hyperlipidemic10  
3 fold increase in TGL and fatty acids. 
50% increase in LDL 
HDL is also increased. 
 
One of the reasons for this increase may be due to the reduction in intestinal 
motility which allows more time for the absorption of fat. Reduction of 
enterohepatic circulation with increased excretion of cholesterol in the bile also 
leads to alteration in lipid profile10.  
 
There is reduction in hepatic lipase & LPL during pregnancy which may 
lead to decrease in the clearance of VLDL and hence increase in VLDL 
(Kinnernen 1980, Herrera et al 1987)10, though the Hypertriglyceridemia is 
principally  due  to  increased  entry  of  TGL –rich  Lipoprotein  into  the 
circulation  (Knopp et al 1982) Normal  pregnancy is a state of  
hyperestrogenemia. 
 
Estrogen  results in  increase  in  HDL  level  and  TGL  level,  decrease  in  
LDL level. 
 
1.  Increased apolipoprotein A-I production      
     Inhibition of activity of hepatic lipase     
 
Increased production of 
mature HDL 
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2.  Increased rate of VLDL production and         
     Decrease in clearance of VLDL                    
 
3.  Increased LDL receptor and         
     increased LDL removal in the liver                                          
 
 
 
4.  Decrease in Lp (a) 
5.  Decrease in apo B 
6.  Increased endothelial production of NO and prostacyclin    vasodilatory 
effect. 
7.  Inhibits oxidation of LDL and protects against toxic effects of oxidized 
LDL on endothelium. 
 
 
 
Hypertriglyceridemia 
 
Decrease in LDL level. 
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Lipid metabolism in PIH   
 
       Pre-eclampsia is associated with insulin resistance & a dramatic increase in  
FFA (antedating clinical expression of the disorder) and plasma TGL well above 
that seen in normal pregnancy. (Lorenzen et al 1995)10,59,60 The changes in 
lipoprotein subfraction are compatible  with changes seen in coronary artery 
disease (Kaaja et al 1995, sattar et al 1997)  
 
1. The dramatic increase in TGL  → increase in VLDL 
       small changes in LDL 
       decrease in HDL 
 
→ Vascular  damage and dysfunction directly &  
→ increased oxidative stress potentiating insulin resistance – Vascular 
dysfunction indirectly( Hayman et al 1999& saltar  & Green 1999)18 
 
Hypoestrogenemia also leads to the above changes8 A significantly higher 
level of LDL was also reported by many workers in third trimester of gestational 
proteinuric hypertension8,19,20,21. 
 
Hypoestogenemia, predominance of smaller and denser serum LDL and 
significant concentration of soluble vascular cell adhesion molecule-1 are 
important contributors for endothetial dysfunction. in PIH (8,19,22,23)  
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Development of atherosclerosis by hypertriglyceridemia in Pre eclampsia  
 
 In preeclampsia  there  is  a  higher  risk of  placental  vasculopathy 24,25 
There is evidence of chronic inflammation, hypercoagulability24-26 and endothelial 
dysfunction27 in persons with metabolic syndrome of which hypertriglyceridemia 
is a major feature.  In lipid –mediated endothelial dysfunction an essential step is 
oxidation of low-density lipoprotein24,28,29. The markers of LDL oxidation and 
circulating serum free fatty acids24,30  are increased in women with  pre- eclampsia. 
 
The atherogenesis itself may be initiated by hypertriglyceridemia.  
Monocytes first adhere to endothelial cells and then transmigrate into the vascular 
intima32,61  For this adhesion which is the initial event, leukocyte and vascular cell 
adhesion molecules such as selectins, integrins, VCAM -1 and ICAM-1 play a 
critical role.  These adhesion molecules are significantly increased in the serum of 
patients with severe hypertriglyceridemia and studies have shown that these 
CAMS are expressed at increased levels in atherosclerotic plaques62-65.  
 
Since Triglyceride related vasculopathy may be one of the etiologic factors 
and positively correlated with the development of pre eclampsia and also may 
influence a future pregnancy as well as a woman’s long term risk of cardiovascular 
disease. It is worthwhile to explore the metabolism and transport of various 
subfractions of lipoproteins in pregnant women from 20 weeks of gestation who 
have developed increase in blood pressure.  
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                                    OBJECTIVE OF THE STUDY  
 
 
 To evaluate the implication of pregnancy induced hypertension on maternal 
plasma lipid profile by comparing with normotensive pregnant women. 
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MATERIALS AND METHODS 
 
The study was carried out in a tertiary care centre, Raja Mirasudar Hospital, 
Thanjavur, attached to our Medical college. 
 
100 women with pregnancy induced Hypertension and 100 normotensive 
pregnant women as controls are included in the study.  
 
The diagnosis of PIH was done as per the norms of American college of 
Obstetrics and Gynecologists.  
 
The definition includes  
1) Systolic Blood pressure ≥140 mm/Hg 
2) Diastolic Blood pressure ≥90 mm/Hg 
Or 
3) increase of ≥30 mm/Hg in Systolic pressure 
                                Or 
4) increase of ≥15 mm/Hg in Diastolic pressure 
 
All the participants   were inquired by a questionnaire  
1) Name of the person 
2) Age of the person 
3) Address 
4) Complaints 
5) Last Menstrual period 
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6) Gravida 
7) Para 
8) Head ache                                                                   
9) Inability to tolerate Bright light Blurred vision                                                        
10) Double vision           
11) Nausea, Vomiting                                                      
12) Right sided upper Quadrant pain       
13) Epigastric pain 
14) Dyspnea          
15) Oliguria                                                            
16) Bleeding tendency 
17) Sudden weight gain 
18) Edema 
19) Tiredness 
 
Previous pregnancy with PIH:                                 
 
1) Diabetic  
2) Hypertensive 
3) Hyperlipidemia 
4) Renal Disease 
5) Hypothyroid 
6) Hepatic Disease 
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FAMILY HISTORY 
1) PIH                                                                     
2) Twins                                                                   
3) Hypertension 
4) Diabetic 
 
DRUG HISTORY: 
1) Thiazides                                                          
2) Retinoid:                                                              
3) ART:    
4) Estrogen: 
5) β-blockers:                                                           
6) Progestin: 
7) Glucocorticoids: 
 
INCLUSION CRITERIA:                                                  
1) Any age   20-45                                                  
2) Any Gravida                                                    
3) After 20 Wks of pregnancy  
4) BP≥140/90 for PIH                                            
5) ≤120/80 control              
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EXCLUSION CRITERIA  
1) Known Diabetic, Hypertensive  
2) Hyperlipidemic before 20 wks.  
3) Edema  
4) Proteinuria, oliguria 
5) Hepatic disease  
6) Involvement of other Organs. 
 
Clinical examination of participants were carried out to rule out Diabetes,  
Hypertension, Hyperlipidemia before 20 wks, edema, proteinuria, oliguria, Hepatic 
disease, involvement of other Organs.  
 
Fasting blood specimen was collected from each participant.  
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METHODOLOGY 
 
DETERMINATION OF GLUCOSE IN SERUM 
 
GOD/POD METHOD 
 
PRINCIPLE 
 
Glucose is oxidized to gluconic acid and hydrogen peroxide in the presence 
of glucose oxidase. Hydrogen peroxide further reacts with phenol and 4-
aminoantipyrine by the catalytic action of peroxidase to form a red coloured 
quinoneimine dye complex. Intensity of the colour formed is directly proportional 
to the amount of glucose present in the sample. 
 
                                 Glucose  
                                 Oxidase 
Glucose+O2+H2O                     Gluconate+ H2O2 
 
                                                          Peroxidase 
H2O2+4 Aminoantipyrine +Phenol                      Red Quinoneimine dye +  H2O       
 
Contents 
L1: Glucose reagent; 4x250ml 
L2: Buffer reagent: 10 ml 
S:lucose standard(100 mg/dl):5ml 
 
Reagent preparation: 
 
2.5ml of Buffer reagent (L2) was added to 250ml of distilled water  
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The contents of one bottle of glucose reagent (L1) was emptied into it, and  
mixed by gentle swirling and allowed to stand at room temperature for 30 
minutes.This working reagent is stable for 60 days when srtored at 2-8° C. 
 
SAMPLE MATERIAL - Serum 
 
PROCEDURE 
 
Wave length/Filter:505nm(Hg 546 nm)Green 
Temperature: 37° C /RT 
Light path:1cm 
 
The working reagent, distilled water, standard and sample were pipetted into clean 
dry test tubes labelled as Blank (B), Standard (S),and Test(T) as follows : 
 
Addition Sequence B (ml) 
S 
(ml) 
T 
(ml) 
Working Reagent 1.0 1.0 1.0 
Distilled water 0.01 --- --- 
Glucose standard -- 0.01 --- 
Sample -- -- 0.01 
 
Mixed well and Incubated at 37° C for 10 minutes. The absorbance of the 
standard (Abs.S) and Test sample (Abs.T) were measured against the blank, within 
60 minutes at 505nm. 
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Calculations: 
Abs.T     
Total glucose in mg/dl =     X 100 
                                Abs.S 
 
Linearity: 
This procedure is linear up to 500mg/dl. 
 
General system parameters 
  
Reaction Type               :  Endpoint 
Reaction Slope              :  Increasing 
Wavelength                   :  505nm  
Incubation   Temp         :  37°C/R.T 
Incubation   Time      :  10 min/30 min 
Sample Vol                   :  10µL 
Reagent Vol                  :  1.0mL 
Std. Concentration        :  100mg/dL 
Zero Setting With        : Reagent Blank  
Linearity   :  500 mg/dl 
 
Reference value 
 
Serum:   Fasting: 74-106 mg/dl 
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ESTIMATION OF CHOLESTEROL 
  
ENZYMATIC METHOD 
 
PRINCIPLE 
                                       Cholesterol 
                                          Esterease 
Cholesterol Ester +H2O Cholesterol +Fatty Acids 
 
                                     Cholesterol 
                                       Oxidase 
Cholesterol +O2 Cholestenone +H2O2 
                                                                                                
                                                                                             Peroxidase 
2H2O2+Phenol+4-Aminoantipyrine                                          Red quinone + 4 - H2O 
 
The concentration of   Cholesterol in the sample is directly proportional to 
the intensity of the red complex   (Red Quinone) which is measured at 500 nm.                                              
    
REAGENTS  
 
Reagent 1 (Enzymes/ Chromogen)  
 
Cholesterol Esterease                                ≥ 200U/L 
Cholesterol Oxidase                                  ≥ 250U/L 
Peroxidase                                                 ≥ 1000U/L 
4-Aminoantipyrine                             0.5 mmol/L 
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Reagent 1A (Buffer): 
 
 Pipes buffer, pH 6.90                                    50 mmol/L   
 Phenol                                                           24mmol/L 
 Sodium Cholate                                            0.5mmol/L 
 
Standard (Cholesterol 200 mg/dL): 
 
 Cholesterol                                                  2 g/L 
 
STORAGE & STABILITY OF THE REAGENTS 
 
 When stored at 2° C-8° C and protected from light, the reagents are stable 
until the expiry dates stated on the labels.    
 
REAGENT RECONSTITUION 
 
 The reagents are allowed to attain room temperature. The contents of one 
bottle of reagents 1 were dissolved with one bottle of reagent 1A and mixed by 
gentle swirling. 
 
RECONSTITUTED REAGENT STORAGE & STABILITY 
 
 The reconstituted reagent is stable for 3 Months when stored at 2°C-8°C. 
 
PROCEDURE 
The samples and the reconstituted reagent were brought to room 
temperature prior to use. 
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The following general system parameters were used with this kit: 
 
General system parameters 
Reaction Type               :  Endpoint 
Reaction Slope              :  Increasing 
Wavelength                   :  500 nm (492-550)  
Flowcell Temp             :  30° C 
Incubation                    :  5 Min. at 37°C 
Sample Vol                   :  10µL 
Reagent Vol                  :  1.0mL 
Std. Concentration        :  200 mg/dL 
Zero Setting With        :  Reagent Blank  
 The instrument was set using above system parameters. 
 The reconstituted reagent, standard and the sample were dispensed in to test 
tubes as follows  
 Blank Standard Test 
Reconstituted 1mL 1mL 1mL 
Standard - 10 µL - 
Sample - - 10 µL 
 
Incubated for 5 minutes at 37° C, mixed and read at 500nm 
Linearity: 
The method is linear up to 500 mg/dL. 
Reference value  for Cholesterol  
Serum/Plasma: Female  20 – 24 yrs : 122-216mg/dl 
    25 – 29yrs : 128-222 mg/dl 
    30-34yrs : 130 – 230 mg/dl 
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ESTIMATION OF TRIGLYCERIDES 
 
ENZYMATIC COLORIMETRIC METHOD 
 
PRINCIPLE 
 
                                   Lipoprotein 
                                       Lipase 
Triglycerides +H2O Glycerol+Fatty Acid 
 
                                Glycerol 
                                  Kinase 
Glycerol +ATP Glycerol-3-Phosphate+ADP 
 
                                               GPO 
Glycerol-3-Phosphate+O2              Dehydroxyacetone Phosphate+ H2O2 
 
                                                                                                Peroxidase 
 2H2O2 + 4- Aminoantipyrine + ADPS               Red quinone + 4H2O 
 
GPO = Glycerol -3- Phosphate Oxidase 
 
ADPS = N-Ethyl-N- Sulfopropyl -n-anisidine 
 
 The intensity of purple coloured complex formed during the reaction is 
directly proportional to the Triglycerides concentration in the sample and is 
measured at 546 nm  
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REAGENTS  
 
Reagent 1 (Enzymes/ Chromogen)  
 
Lipoprotein Lipase                                  ≥ 1100U/L 
Glycerol Kinase                                       ≥ 800U/L 
Glycerol-3- Phosphate Oxidase               ≥ 5000U/L 
Peroxidase                                                ≥ 350U/L 
4-Aminoantipyrine                      0.7 mmol/L 
ATP                                                          0.3 mmol/L      
 
Reagent 1A (Buffer) 
 
 Pipes buffer, pH 7.50                          50 mmol/L   
ADPS                                                        1 mmol/L 
Magnesium salt                                         15 mmol/L 
 
Standard (Triglycerides 200 mg/dL) 
 
Glycerol (Trig. equivalent)   2 g/L 
 
REAGENT RECONSTITUION 
 
 The reagents are allowed to attain room temperature. The contents of one 
bottle of reagents 1 were dissolved with one bottle of reagent 1A, and mixed by 
gentles swirling and used after 5 minutes. 
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RECONSTITUTED REAGENT STORAGE & STABILITY 
 
 The reconstituted reagent is stable for 6 weeks when stored at 2°C-8°C. 
 
PROCEDURE 
 The samples and the reconstituted reagent were brought to room 
temperature prior to use. 
 
The following general system parameters were used with this kit: 
 
General system parameters 
 
Reaction Type              :  Endpoint 
Reaction Slope              :  Increasing 
Wavelength                   :  546 nm (520-570) 
Flowcell Temp              :  30° C 
Incubation                     :  5 Min. at 37°C 
Sample Vol                   :  10µL 
Reagent Vol                  :  1.0mL 
Std. Concentration        :  200 mg/dL 
Zero Setting With         :  Reagent Blank  
The instrument was set using above system parameters. 
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The reconstituted reagent, standard and sample were dispensed in to test tubes as 
follows :  
 
 Blank Standard Test 
Reconstituted reagent 1mL 1mL 1mL 
Standard - 10 µL - 
Sample - - 10 µL 
 
 Incubated for 5 minutes at 37° C. Mixed and read at 546nm. The final 
colour was stable for at least 30 minutes. 
 
Linearity: 
The method is linear up to 1000 mg/dL. 
 
Reference value for Triglycerides:  
Serum/ Plasma  
Females:  20 – 29yrs = 37 - 144 mg/dl 
  30 – 39yrs = 39 - 176 mg/dl 
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ESTIMATION OF HDL-CHOLESTEROL 
 
PHOSPHOTUNGSTATE METHOD 
 
PRINCIPLE 
 
Chylomicrons, VLDL (Very Low Density Lipoproteins) and LDL fractions 
in serum or plasma are separated from HDL by precipitating with Phosphotungstic 
Acid and Magnesium Chloride. After centrifugation, the cholesterol in the HDL 
fraction, which remains in the supernatant, is assayed with enzymatic cholesterol 
method, using Cholesterol Esterase, Cholesterol Oxidase, Peroxidase and the 
chromogen 4- Aminoantipyrine/Phenol. 
 
REAGENTS 
 
Reagent 1(Enzymes/Chromogen) 
 
Cholesterol esterase         ≥ 200 U/L 
Cholesterol Oxidase        ≥ 250 U/L 
Peroxidase                        ≥ 1000 U/L 
4-Aminoantipyrine           0.5mmol/L 
 
Reagent 1A (Buffer): 
 
Pipes buffer, pH 6.9           50 mmol/L 
Phenol                                24 mmol/L 
Sodium Cholate                 0.5mmol/L 
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Reagent 2 (Precipating Reagent) 
 
Phosphotungstic Acid        2.4 mmol/L 
Magnesium Chloride         39 mmol/L 
 
Standard (HDL Cholesterol 50mg/dL): 
 
Cholesterol                      0.5g/L 
 
REAGENT RECONSTITUTION: 
 
The reagents are allowed to attain the room temperature. The contents of 
one bottle of reagent 1 is dissolved into one bottle of reagent 1A, and mixed by 
gentle swirling till completely dissolved and used after 5 minutes  
 
RECONSTITUITED REAGENT STORAGE & STABILITY 
 
The reconstituted reagent was stable for 3 months when stored at 2°C-8 °C. 
 
PROCEDURE 
 
The samples, the participating reagent 2 and the reconstituted reagent were 
brought to room temperature prior to use. 
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I. PRECIPITATION 
 
The sample and precipitating reagent were dispensed into Centrifuge Tube as 
follows: 
 Test 
Sample 0.20 mL(200µL) 
Precipitating Reagent 2 0.20 mL(200µL) 
 
Mixed well and centrifuged at 1500 g or 3500-4000 rpm for 10 min. The clear 
supernatant was separated  immediately and determined the Cholesterol content as 
for total cholesterol estimation.  
 
II  CHOLESTEROL ASSAY 
 
The following general system parameters were used with this kit: 
 
General System Parameters 
Reaction Type                  :   End point 
Reaction Slope                 :   Increasing 
Wavelength                      :  500 nm (492-550nm) 
Flow cell Temp                :  30°C 
Incubation                        :  5Min 37°C 
Sample Vol (Supernatant) :  20µL 
Reagent Vol                     :  1.0 mL 
Std.Concetration             : 100mg/dL(The Std.of 50 mg/dL is to be fed as  
100 mg/dL to account for the dilution of sample 
in the precipitation step)    
Zero Setting With           :  Reagent Blank 
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The instrument was set using above system parameters. 
 
The reconstituted reagent, standard and supernatent were dispensed into test tubes 
as follows: 
 
 Blank Standard Test 
Reconstituted Reagent 1 mL 1 mL 1 mL 
Standard - 20µL -- 
Supernatant - - 20µL 
 
Incubate for 5 minutes at 37°C, mixed and read at 500nm. 
 
Reference value in HDL-Cholesterol: 
Serum/Plasma; Female :  20-24 yrs : 33 – 79 mg/dl 
    25 – 29yrs : 37-83 mg/dl 
    30-34 yrs : 36-77 mg/dl 
 
ESTIMATION OF LDL CHOLESTEROL BY 
FRIEDWALD EQUATION 
[LDL CHOLESTEROL]= [Total cholesterol] -[HDL cholesterol] - 
[Triglyceride/5], all concentrations are in mg/dl. 
VLDL = Triglyceride/5 
 
Reference Value :  
 Female =   20 - 24 yrs : 57 - 159 mg/dl 
   25 - 29 yrs : 71 - 164 mg/dl 
   30 - 34 yrs : 70 - 156 mg/dl 
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ESTIMATION OF URIC ACID 
 
ENZYMATIC METHOD 
 
PRINCIPLE 
 
Uric acid is converted by uricase into allantoin and hydrogen peroxide 
which in presence of peroxidase (POD) oxidises  the chromogen to a red coloured 
compound which is read at 500 nm (492-550).The final colour of the reaction is 
stable for 15 minutes.                    
 
                                      Uricase 
Uric acid +2H2O+O2                              Allantoin+CO2 +H2O2 
 
                                                         POD 
2H2O2+Aminoantipyrine+DHBS          Red quinone+ H2O+HCI 
 
 DHBS=3.5-Dichloro-2-Hydroxybenzene Sulfonic Acid 
 
REAGENTS 
 
Reagent 1(Enzymes/Chromogen) 
 
Uricase                    ≥ 60 U/L 
Peroxidase               ≥ 660 U/L 
4-Aminoantipyrine   0.23mmol/L 
 
Reagent 1A (Buffer) 
 
Phosphate buffer, pH 7.5      50 mmol/L 
DHBS                                     2 mmol/L 
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Standard (Uric Acid 6mg/dL) 
 
Uric Acid               : 0.06g/L 
 
STORAGE & STABILITY OF THE REAGENTS 
 
When stored at 2°C-8 °C and protected from light, the reagents are stable 
until the expiry dates stated on the labels. 
 
REAGENT RECONSTITUTION: 
 
The reagents are allowed to attain the room temperature. The contents of 
one bottle of reagent 1 is dissolved with one bottle of reagent 1A. 
 
RECONSTITUITED REAGENT STORAGE & STABILITY 
 
The reconstituted reagent was stable for 4 weeks when stored at 2°C-8 °C. 
 
PROCEDURE 
 
The sample and the reconstituted reagent were brought to room temperature 
prior to use. The following general system parameters were used with this kit: 
 
General System Parameters 
 
Reaction Type      :   End point 
Reaction Slope     :   Increasing 
Wavelength          :  510 nm (492-550) 
Flow cell Temp      :  30°C 
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Incubation              :  5Min.at 37°C 
Sample Vol           :  25µL 
Reagent Vol           :  1mL 
Std.Concetration     : 6mg/dL 
Zero Setting With   :  Reagent Blank 
The instrument was set using above system parameters. 
 
The reconstituted reagent, standard and sample were dispensed into test tubes as 
follows : 
 
 Blank Standard Test 
Reconstituted Reagent 1 mL 1 mL 1 mL 
Standard - 25µL -- 
Sample - - 25µL 
 
Incubated for 5 min. at 37°C.Mix and read at 510nm 
The final colour is stable for at least 15 minutes. 
 
Linearity: 
The method is linear up to 25 mg/dL. 
 
Reference value in Serum/Plasma 
 
Males     : 3.5 - 7.2 mg/dL 
Females : 2.6 - 6.0 mg/dL 
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RESULTS 
LIPID PROFILE IN PIH 
Sl.No AGE LMP (WEEKS) BP FBS TC TGL HDL LDL VLDL TC/HDL TGL/HDL HDL/VLDL UA LDL/HDL
1 33 32 144/92 83.5 181 280 40 85 56 4.53 7.00 0.71 4.1 2.13 
2 28 28 140/90 73.6 216 299 40 116.2 59.8 5.40 7.48 0.67 2.8 2.91 
3 20 32 140/90 57 258 373 28 155.4 74.6 9.21 13.32 0.38 4.4 5.55 
4 25 28 140/100 110 214 268 38 122.4 53.6 5.63 7.05 0.71 3.1 3.22 
5 27 32 140/90 79 249 328 36 147.4 65.6 6.92 9.11 0.55 4.7 4.09 
6 23 32 140/90 82 252 290 40 154 58 6.30 7.25 0.69 4.1 3.85 
7 28 32 140/94 104 210 520 35 71 104 6.00 14.86 0.34 3.8 2.03 
8 28 22 140/90 83 261 290 42 161 58 6.21 6.90 0.72 3.7 3.83 
9 22 20 140/90 98 190 400 37 73 80 5.14 10.81 0.46 3 1.97 
10 25 32 150/120 91 232 580 40 76 116 5.80 14.50 0.34 7.6 1.90 
11 26 32 140/90 102 188 540 34 46 108 5.53 15.88 0.31 8.5 1.35 
12 27 32 140/90 86 193 440 30 75 88 6.43 14.67 0.34 4.4 2.50 
13 24 28 140/100 100 244 480 35 113 96 6.97 13.71 0.36 4.7 3.23 
14 27 24 140/90 81 181 297 30 91.6 59.4 6.03 9.90 0.51 5.3 3.05 
15 24 32 140/90 80 189 264 25 111.2 52.8 7.56 10.56 0.47 4 4.45 
16 25 28 140/90 64 182 333 40 75.4 66.6 4.55 8.33 0.60 3.7 1.89 
17 22 32 140/90 70 187 254 40 96.2 50.8 4.68 6.35 0.79 4.7 2.41 
18 22 28 140/94 75 230 250 29 151 50 7.93 8.62 0.58 3.6 5.21 
19 22 32 140/90 68 206 286 39 109.8 57.2 5.28 7.33 0.68 4 2.82 
20 23 24 144/90 68 197 294 57 81.2 58.8 3.46 5.16 0.97 4.9 1.42 
21 20 32 140/100 70 272 316 38 170.8 63.2 7.16 8.32 0.60 4.6 4.49 
22 23 32 140/90 90 268 455 20 157 91 13.40 22.75 0.22 4.2 7.85 
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23 24 28 140/100 98 275 406 38 155.8 81.2 7.24 10.68 0.47 9 4.10 
24 25 34 140/96 100 207 270 45 108 54 4.60 6.00 0.83 5.4 2.40 
25 25 34 150/100 100 196 261 38 105.8 52.2 5.16 6.87 0.73 6.8 2.78 
26 20 32 140/100 100 223 290 50 115 58 4.46 5.80 0.86 4 2.30 
27 32 24-26 160/100 100 180 299 40 80.2 59.8 4.50 7.48 0.67 9.3 2.01 
28 25 26 150/100 98 194 291 40 95.8 58.2 4.85 7.28 0.69 4.7 2.40 
29 22 26-28 140/94 98 192 294 30 103.2 58.8 6.40 9.80 0.51 3.2 3.44 
30 24 28-30 140/90 86 165 280 28 81 56 5.89 10.00 0.50 3.9 2.89 
31 25 32 144/90 90 206 370 35 97 74 5.89 10.57 0.47 9.7 2.77 
32 23 28 140/94 98 188 281 31 100.8 56.2 6.06 9.06 0.55 5.46 3.25 
33 23 20-22 140/94 66 187 301 46 80.8 60.2 4.07 6.54 0.76 5.04 1.76 
34 26 24 140/90 68 192 284 27 108.2 56.8 7.11 10.52 0.48 2.52 4.01 
35 25 28-30 140/96 104 150 300 47 43 60 3.19 6.38 0.78 4.62 0.91 
36 20 32 140/90 76 193 292 44 90.6 58.4 4.39 6.64 0.75 1.68 2.06 
37 22 24-26 140/90 82 179 315 60 56 63 2.98 5.25 0.95 2.1 0.93 
38 32 28-30 140/94 68 228 280 37 135 56 6.16 7.57 0.66 2.1 3.65 
39 25 28 140/94 90 153 340 33 52 68 4.64 10.30 0.49 3.78 1.58 
40 20 28-30 140/90 90 176 367 40 62.6 73.4 4.40 9.18 0.54 2.94 1.57 
41 22 32 140/98 74 215 314 50 102.2 62.8 4.30 6.28 0.80 3.78 2.04 
42 34 24 140/90 62 180 329 38 76.2 65.8 4.74 8.66 0.58 9.4 2.01 
43 25 28 140/90 98 251 394 38 134.2 78.8 6.61 10.37 0.48 5.46 3.53 
44 23 24 140/94 90 252 286 28 166.8 57.2 9.00 10.21 0.49 5.3 5.96 
45 `23 28 140/90 94 202 250 37 115 50 5.46 6.76 0.74 4.8 3.11 
46 21 32 140/90 90 241 377 35 130.6 75.4 6.89 10.77 0.46 7.2 3.73 
47 23 28 140/100 94 191 430 50 55 86 3.82 8.60 0.58 8.6 1.10 
48 24 32 140/96 98 276 361 37 166.8 72.2 7.46 9.76 0.51 6.9 4.51 
49 23 32 140/90 68 185 367 36 75.6 73.4 5.14 10.19 0.49 7 2.10 
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50 27 28 142/100 72 200 396 30 90.8 79.2 6.67 13.20 0.38 7.8 3.03 
51 25 32 144/90 90 206 370 35 97 74 5.89 10.57 0.47 9.7 2.77 
52 23 20-22 140/94 66 187 301 46 80.8 60.2 4.07 6.54 0.76 5.04 1.76 
53 25 28-30 140/96 104 150 300 47 43 60 3.19 6.38 0.78 4.62 0.91 
54 22 24-26 140/90 82 179 315 60 56 63 2.98 5.25 0.95 2.1 0.93 
55 25 28 140/94 90 153 340 33 52 68 4.64 10.30 0.49 3.78 1.58 
56 23 32 140/90 68 185 367 36 75.6 73.4 5.14 10.19 0.49 7 2.10 
57 23 28 140/100 94 191 430 50 55 86 3.82 8.60 0.58 8.6 1.10 
58 `23 28 140/90 94 202 250 37 115 50 5.46 6.76 0.74 4.8 3.11 
59 25 28 140/90 98 251 394 38 134.2 78.8 6.61 10.37 0.48 5.46 3.53 
60 22 32 140/98 74 215 314 50 102.2 62.8 4.30 6.28 0.80 3.78 2.04 
61 20 32 140/100 70 272 316 38 170.8 63.2 7.16 8.32 0.60 4.6 4.49 
62 24 28 140/100 98 275 406 38 155.8 81.2 7.24 10.68 0.47 9 4.10 
63 25 34 150/100 100 196 261 38 105.8 52.2 5.16 6.87 0.73 6.8 2.78 
64 32 24-26 160/100 100 180 299 40 80.2 59.8 4.50 7.48 0.67 9.3 2.01 
65 22 26-28 140/94 98 192 294 30 103.2 58.8 6.40 9.80 0.51 3.2 3.44 
66 33 32 144/92 83.5 181 280 40 85 56 4.53 7.00 0.71 4.1 2.13 
67 20 32 140/90 57 258 373 28 155.4 74.6 9.21 13.32 0.38 4.4 5.55 
68 27 32 140/90 79 249 328 36 147.4 65.6 6.92 9.11 0.55 4.7 4.09 
69 28 32 140/94 104 210 520 35 71 104 6.00 14.86 0.34 3.8 2.03 
70 22 20 140/90 98 190 400 37 73 80 5.14 10.81 0.46 3 1.97 
71 22 32 140/90 68 206 286 39 109.8 57.2 5.28 7.33 0.68 4 2.82 
72 22 32 140/90 70 187 254 40 96.2 50.8 4.68 6.35 0.79 4.7 2.41 
73 24 32 140/90 80 189 264 25 111.2 52.8 7.56 10.56 0.47 4 4.45 
74 24 28 140/100 100 244 480 35 113 96 6.97 13.71 0.36 4.7 3.23 
75 26 32 140/90 102 188 540 34 46 108 5.53 15.88 0.31 8.5 1.35 
76 27 28 142/100 72 200 396 30 90.8 79.2 6.67 13.20 0.38 7.8 3.03 
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77 24 32 140/96 98 276 361 37 166.8 72.2 7.46 9.76 0.51 6.9 4.51 
78 21 32 140/90 90 241 377 35 130.6 75.4 6.89 10.77 0.46 7.2 3.73 
79 23 24 140/94 90 252 286 28 166.8 57.2 9.00 10.21 0.49 5.3 5.96 
80 34 24 140/90 62 180 329 38 76.2 65.8 4.74 8.66 0.58 9.4 2.01 
81 20 28-30 140/90 90 176 367 40 62.6 73.4 4.40 9.18 0.54 2.94 1.57 
82 25 32 150/120 91 232 580 40 76 116 5.80 14.50 0.34 7.6 1.90 
83 28 22 140/90 83 261 290 42 161 58 6.21 6.90 0.72 3.7 3.83 
84 23 32 140/90 82 252 290 40 154 58 6.30 7.25 0.69 4.1 3.85 
85 25 28 140/100 110 214 268 38 122.4 53.6 5.63 7.05 0.71 3.1 3.22 
86 28 28 140/90 73.6 216 299 40 116.2 59.8 5.40 7.48 0.67 2.8 2.91 
87 24 28-30 140/90 86 165 280 28 81 56 5.89 10.00 0.50 3.9 2.89 
88 23 28 140/94 98 188 281 31 100.8 56.2 6.06 9.06 0.55 5.46 3.25 
89 26 24 140/90 68 192 284 27 108.2 56.8 7.11 10.52 0.48 2.52 4.01 
90 20 32 140/90 76 193 292 44 90.6 58.4 4.39 6.64 0.75 1.68 2.06 
91 32 28-30 140/94 68 228 280 37 135 56 6.16 7.57 0.66 2.1 3.65 
92 27 32 140/90 86 193 440 30 75 88 6.43 14.67 0.34 4.4 2.50 
93 27 24 140/90 81 181 297 30 91.6 59.4 6.03 9.90 0.51 5.3 3.05 
94 25 28 140/90 64 182 333 40 75.4 66.6 4.55 8.33 0.60 3.7 1.89 
95 22 28 140/94 75 230 250 29 151 50 7.93 8.62 0.58 3.6 5.21 
96 23 24 144/90 68 197 294 57 81.2 58.8 3.46 5.16 0.97 4.9 1.42 
97 25 26 150/100 98 194 291 40 95.8 58.2 4.85 7.28 0.69 4.7 2.40 
98 20 32 140/100 100 223 290 50 115 58 4.46 5.80 0.86 4 2.30 
99 25 34 140/96 100 207 270 45 108 54 4.60 6.00 0.83 5.4 2.40 
100 23 32 140/90 90 268 455 20 157 91 13.40 22.75 0.22 4.2 7.85 
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CONTROL 
Sl.No AGE LMP (WEEKS) BP FBS TC TGL HDL LDL VLDL TC/HDL TGL/HDL HDL/VLDL UA LDL/HDL
1 25 28 110/90 112 200 188 40 122.4 37.6 5.00 4.70 1.06 4.3 3.06 
2 22 28 110/70 79 177 230 34 97 46 5.21 6.76 0.74 3.4 2.85 
3 21 32 120/80 107 157 200 40 77 40 3.93 5.00 1.00 4.7 1.93 
4 18 28 130/90 70 173 180 31 106 36 5.58 5.81 0.86 3 3.42 
5 22 24 120/80 65 191 200 40 111 40 4.78 5.00 1.00 3.2 2.78 
6 23 28-30 120/70 101 189 210 42 105 42 4.50 5.00 1.00 5.3 2.50 
7 20 28-30 110/80 100 185 149 46 109.2 29.8 4.02 3.24 1.54 3.9 2.37 
8 24 28 120/70 98 172 212 40 89.6 42.4 4.30 5.30 0.94 3.4 2.24 
9 24 26-28 120/70 80 200 137 40 132.6 27.4 5.00 3.43 1.46 3.4 3.32 
10 25 28 110/70 102 175 177 56 83.6 35.4 3.13 3.16 1.58 4.5 1.49 
11 22 28 110/70 100 197 176 47 114.8 35.2 4.19 3.74 1.34 2.1 2.44 
12 20 24 110/70 96 149 200 60 49 40 2.48 3.33 1.50 3.2 0.82 
13 26 28-30 120/70 104 115 114 60 32.2 22.8 1.92 1.90 2.63 4.2 0.54 
14 32 26-28 130/80 100 189 251 43 95.8 50.2 4.40 5.84 0.86 3 2.23 
15 24 24-26 110/70 98 160 180 47 77 36 3.40 3.83 1.31 2.14 1.64 
16 23 20-22 120/70 104 174 233 43 84.4 46.6 4.05 5.42 0.92 3 1.96 
17 27 28-30 110/70 84 171 156 52 87.8 31.2 3.29 3.00 1.67 3 1.69 
18 21 32 120/70 70 110 210 45 23 42 2.44 4.67 1.07 2.57 0.51 
19 25 28 110/70 68 160 157 42 86.6 31.4 3.81 3.74 1.34 2.57 2.06 
20 23 24-26 120/70 70 195 215 60 92 43 3.25 3.58 1.40 4.2 1.53 
21 25 22-24 110/70 90 163 187 55 70.6 37.4 2.96 3.40 1.47 2.1 1.28 
22 25 24 130/90 100 209 267 47 108.6 53.4 4.45 5.68 0.88 3.36 2.31 
23 24 24-26 130/90 96 240 222 58 137.6 44.4 4.14 3.83 1.31 5.04 2.37 
24 23 28 120/80 78 163 216 54 65.8 43.2 3.02 4.00 1.25 2.52 1.22 
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25 35 26-28 120/70 98 135 188 40 57.4 37.6 3.38 4.70 1.06 2.94 1.44 
26 28 32 130/90 100 123 232 50 26.6 46.4 2.46 4.64 1.08 3.78 0.53 
27 20 24-26 110/70 76 126 171 47 44.8 34.2 2.68 3.64 1.37 3.78 0.95 
28 28 24 120/80 96 160 125 46 89 25 3.48 2.72 1.84 2.1 1.93 
29 21 28-30 130/90 70 187 260 50 85 52 3.74 5.20 0.96 4.2 1.70 
30 25 28-30 130/80 98 208 236 32 128.8 47.2 6.50 7.38 0.68 3.8 4.03 
31 28 24-26 110/70 74 200 186 55 107.8 37.2 3.64 3.38 1.48 3.6 1.96 
32 23 28-30 120/70 96 206 158 40 134.4 31.6 5.15 3.95 1.27 2.9 3.36 
33 21 28 110/80 80 186 160 40 114 32 4.65 4.00 1.25 3.78 2.85 
34 32 28 110/70 98 216 204 58 117.2 40.8 3.72 3.52 1.42 5.1 2.02 
35 23 28 110/70 68 160 165 52 75 33 3.08 3.17 1.58 4.5 1.44 
36 20 22-24 110/*70 90 191 156 49 110.8 31.2 3.90 3.18 1.57 3.6 2.26 
37 28 30-32 120/70 86 180 162 64 83.6 32.4 2.81 2.53 1.98 4.8 1.31 
38 20 28 110/80 104 200 168 57 109.4 33.6 3.51 2.95 1.70 2.9 1.92 
39 23 28 110/70 70 162 165 55 74 33 2.95 3.00 1.67 3.8 1.35 
40 23 24 120/80 76 158 191 55 64.8 38.2 2.87 3.47 1.44 3.56 1.18 
41 24 24 130/90 62 197 273 52 90.4 54.6 3.79 5.25 0.95 2.75 1.74 
42 29 32 120/70 72 104 193 48 17.4 38.6 2.17 4.02 1.24 2.7 0.36 
43 24 32 130/90 90 140 246 36 54.8 49.2 3.89 6.83 0.73 4.2 1.52 
44 21 30 110/80 92 186 212 40 103.6 42.4 4.65 5.30 0.94 3.6 2.59 
45 19 32 130/90 78 180 200 50 90 40 3.60 4.00 1.25 3.8 1.80 
46 20 32 110/90 80 146 190 55 53 38 2.65 3.45 1.45 3.7 0.96 
47 26 28 120/80 88 156 190 45 73 38 3.47 4.22 1.18 3.8 1.62 
48 27 32 120/80 96 191 258 45 94.4 51.6 4.24 5.73 0.87 5 2.10 
49 20 32 110/80 110 246 254 39 156.2 50.8 6.31 6.51 0.77 3.2 4.01 
50 23 32 110/70 90 200 264 53 94.2 52.8 3.77 4.98 1.00 4.8 1.78 
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51 28 24-26 110/70 74 200 186 55 107.8 37.2 3.64 3.38 1.48 3.6 1.96 
52 21 28 110/80 80 186 160 40 114 32 4.65 4.00 1.25 3.78 2.85 
53 23 28 110/70 68 160 165 52 75 33 3.08 3.17 1.58 4.5 1.44 
54 28 30-32 120/70 86 180 162 64 83.6 32.4 2.81 2.53 1.98 4.8 1.31 
55 23 28 110/70 70 162 165 55 74 33 2.95 3.00 1.67 3.8 1.35 
56 20 32 110/80 110 246 254 39 156.2 50.8 6.31 6.51 0.77 3.2 4.01 
57 26 28 120/80 88 156 190 45 73 38 3.47 4.22 1.18 3.8 1.62 
58 19 32 130/90 78 180 200 50 90 40 3.60 4.00 1.25 3.8 1.80 
59 24 32 130/90 90 140 246 36 54.8 49.2 3.89 6.83 0.73 4.2 1.52 
60 24 24 130/90 62 197 273 52 90.4 54.6 3.79 5.25 0.95 2.75 1.74 
61 25 22-24 110/70 90 163 187 55 70.6 37.4 2.96 3.40 1.47 2.1 1.28 
62 24 24-26 130/90 96 240 222 58 137.6 44.4 4.14 3.83 1.31 5.04 2.37 
63 35 26-28 120/70 98 135 188 40 57.4 37.6 3.38 4.70 1.06 2.94 1.44 
64 20 24-26 110/70 76 126 171 47 44.8 34.2 2.68 3.64 1.37 3.78 0.95 
65 21 28-30 130/90 70 187 260 50 85 52 3.74 5.20 0.96 4.2 1.70 
66 25 28 110/90 112 200 188 40 122.4 37.6 5.00 4.70 1.06 4.3 3.06 
67 21 32 120/80 107 157 200 40 77 40 3.93 5.00 1.00 4.7 1.93 
68 22 24 120/80 65 191 200 40 111 40 4.78 5.00 1.00 3.2 2.78 
69 20 28-30 110/80 100 185 149 46 109.2 29.8 4.02 3.24 1.54 3.9 2.37 
70 24 26-28 120/70 80 200 137 40 132.6 27.4 5.00 3.43 1.46 3.4 3.32 
71 25 28 110/70 68 160 157 42 86.6 31.4 3.81 3.74 1.34 2.57 2.06 
72 27 28-30 110/70 84 171 156 52 87.8 31.2 3.29 3.00 1.67 3 1.69 
73 24 24-26 110/70 98 160 180 47 77 36 3.40 3.83 1.31 2.14 1.64 
74 26 28-30 120/70 104 115 114 60 32.2 22.8 1.92 1.90 2.63 4.2 0.54 
75 22 28 110/70 100 197 176 47 114.8 35.2 4.19 3.74 1.34 2.1 2.44 
76 23 32 110/70 90 200 264 53 94.2 52.8 3.77 4.98 1.00 4.8 1.78 
 50
77 27 32 120/80 96 191 258 45 94.4 51.6 4.24 5.73 0.87 5 2.10 
78 20 32 110/90 80 146 190 55 53 38 2.65 3.45 1.45 3.7 0.96 
79 21 30 110/80 92 186 212 40 103.6 42.4 4.65 5.30 0.94 3.6 2.59 
80 29 32 120/70 72 104 193 48 17.4 38.6 2.17 4.02 1.24 2.7 0.36 
81 23 24 120/80 76 158 191 55 64.8 38.2 2.87 3.47 1.44 3.56 1.18 
82 25 28 110/70 102 175 177 56 83.6 35.4 3.13 3.16 1.58 4.5 1.49 
83 24 28 120/70 98 172 212 40 89.6 42.4 4.30 5.30 0.94 3.4 2.24 
84 23 28-30 120/70 101 189 210 42 105 42 4.50 5.00 1.00 5.3 2.50 
85 18 28 130/90 70 173 180 31 106 36 5.58 5.81 0.86 3 3.42 
86 22 28 110/70 79 177 230 34 97 46 5.21 6.76 0.74 3.4 2.85 
87 25 28-30 130/80 98 208 236 32 128.8 47.2 6.50 7.38 0.68 3.8 4.03 
88 23 28-30 120/70 96 206 158 40 134.4 31.6 5.15 3.95 1.27 2.9 3.36 
89 32 28 110/70 98 216 204 58 117.2 40.8 3.72 3.52 1.42 5.1 2.02 
90 20 22-24 110/*70 90 191 156 49 110.8 31.2 3.90 3.18 1.57 3.6 2.26 
91 20 28 110/80 104 200 168 57 109.4 33.6 3.51 2.95 1.70 2.9 1.92 
92 20 24 110/70 96 149 200 60 49 40 2.48 3.33 1.50 3.2 0.82 
93 32 26-28 130/80 100 189 251 43 95.8 50.2 4.40 5.84 0.86 3 2.23 
94 23 20-22 120/70 104 174 233 43 84.4 46.6 4.05 5.42 0.92 3 1.96 
95 21 32 120/70 70 110 210 45 23 42 2.44 4.67 1.07 2.57 0.51 
96 23 24-26 120/70 70 195 215 60 92 43 3.25 3.58 1.40 4.2 1.53 
97 28 24 120/80 96 160 125 46 89 25 3.48 2.72 1.84 2.1 1.93 
98 28 32 130/90 100 123 232 50 26.6 46.4 2.46 4.64 1.08 3.78 0.53 
99 23 28 120/80 78 163 216 54 65.8 43.2 3.02 4.00 1.25 2.52 1.22 
100 25 24 130/90 100 209 267 47 108.6 53.4 4.45 5.68 0.88 3.36 2.31 
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TABLE - 1 
 
 
COMPARISON OF TOTAL CHOLESTEROL BETWEEN PIH AND 
CONTROL GROUPS 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
 
Mean Std. Deviation
Std. 
Error 
Mean
Upper Lower 
t df Sig.  (2-tailed) 
TC in 
PIH 209.54 
Pair 1 
TC in 
Control 175.16 
34.380 43.849 4.385 25.679 43.081 7.841 99 (P<0.0001) 
 
 
Total Cholesterol is significantly elevated in PIH group compared to control (p< 0.0001)  
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TABLE - 2 
 
 
COMPARISON OF TRIGLYCERIDES BETWEEN PIH AND  
CONTROL GROUPS 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation
Std. 
Error 
Mean
Upper Lower 
t df Sig.  (2-tailed) 
TGL  
in PIH 337.24 Pair 
2 TGL  
in 
Control 
197.48 
139.760 88.432 8.843 122.213 157.307 15.804 99 (P<0.0001)
 
 
Triglycerides is significantly elevated in PIH group compared to control (p< 0.0001)  
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TABLE - 3 
 
 
COMPARISON OF HDL BETWEEN PIH AND CONTROL GROUPS 
 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation 
Std. 
Error 
Mean
Upper Lower 
t df Sig.  (2-tailed) 
HDL  
in PIH  37.62 Pair 
3 HDL  
in 
Control 
47.50 
-9.880 9.679 .968 -11.801 -7.959 -10.208 99 (P<0.0001)
 
 
HDL is significantly decreased in PIH group compared to control (p< 0.0001)  
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TABLE - 4 
 
 
COMPARISON OF LDL BETWEEN PIH AND CONTROL GROUPS 
 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation
Std. 
Error 
Mean 
Upper Lower 
t df Sig.  (2-tailed) 
LDL  in 
PIH 104.47 Pair 
4 LDL  in 
Control 88.164 
16.308 46.285 4.629 7.124 25.492 3.523 99 (P<0.0001)
 
 
LDL is significantly elevated in PIH group compared to control (p< 0.0001)  
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TABLE - 5 
 
 
COMPARISON OF VLDL BETWEEN PIH AND CONTROL GROUPS 
 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation
Std. 
Error 
Mean
Upper Lower 
t df Sig.  (2-tailed) 
VLDL  
in PIH  67.45 Pair 
5 VLDL  
in 
Control 
39.496 
27.952 17.687 1.769 24.443 31.461 15.804 99 (P<0.0001)
 
VLDL is significantly elevated in PIH group compared to control (p< 0.0001)  
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TABLE - 6 
 
 
COMPARISON OF TC/HDL RATIO BETWEEN PIH AND  
CONTROL GROUPS 
 
 
Paired Differences 
95% Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation
Std. 
Error 
Mean Upper Lower 
t df Sig.  (2-tailed) 
TC/HDL  
in PIH  5.843 Pair 
6 TC/HDL  
in 
Control 
3.81 
2.0379 1.881 .188 1.665 2.411 10.833 99 (P<0.0001)
 
 
TC/HDL Ratio is significantly elevated in PIH group compared to control (p< 0.0001)  
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TABLE - 7 
 
 
COMPARISON OF TGL/HDL RATIO BETWEEN PIH AND  
CONTROL GROUPS 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation
Std. 
Error 
Mean
Upper Lower 
t df Sig.  (2-tailed) 
TGL/HDL  
in PIH  9.41 
Pair 
7 
TGL/HDL  
in Control 4.302 
5.110 3.437 .3437 4.428 5.792 14.866 99 (P<0.0001) 
 
TGL/HDL Ratio is significantly elevated in PIH group compared to control (p< 0.0001)  
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TABLE - 8 
 
 
COMPARISON OF HDL/VLDL BETWEEN PIH AND  
CONTROL GROUPS 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation
Std. 
Error 
Mean
Upper Lower 
t df Sig.  (2-tailed) 
HDL/ 
VLDL in 
PIH 
.5846 
Pair 
8 HDL/ 
VLDL  in 
Control 
1.2571 
-.673 .397 .040 -.751 -.594 -16.941 99 (P<0.0001)
 
 
HDL/VLDL  is significantly decreased in PIH group compared to control (p< 0.0001)  
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TABLE - 9 
 
 
COMPARISON OF URIC ACID BETWEEN PIH AND CONTROL 
GROUPS 
 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation
Std. 
Error 
Mean
Upper Lower 
t df Sig.  (2-tailed) 
UA   in 
PIH  5.008 Pair 
9 UA  in 
Control 3.576 
1.432 2.164 .216 1.002 1.861 6.616 99 (P<0.0001)
 
 
Uric Acid is significantly elevated in PIH group compared to control (p< 0.0001) 
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TABLE - 10 
 
 
COMPARISON OF LDL/HDL RATIO BETWEEN PIH AND  
CONTROL GROUPS 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation
Std. 
Error 
Mean
Upper Lower 
t df Sig.  (2-tailed) 
LDL/HDL  
in PIH  2.961 Pair 
10 LDL/HDL 
in Control 1.945 
1.016 1.543 .154 .710 1.322 6.584 99 (P<0.001)
 
 
LDL/HDL in PIH is significantly elevated in PIH group compared to control (p< 0.0001)  
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TABLE - 11 
 
COMPARISON OF FBS BETWEEN PIH AND  
CONTROL GROUPS 
 
Paired Differences 
95% 
Confidence 
Interval of the 
Difference 
   
Mean Std. Deviation
Std. 
Error 
Mean 
Upper Lower 
t df Sig.  (2-tailed) 
FBS in 
PIH  85.342 Pair 
11 FBS in 
Control 88.20 
-2.8580 19.31 1.930 -6.690 .9736 -1.480 99 (P>0.001) 
 
 
FBS in PIH is not significantly altered, when compared to FBS in control (P> 0.0001)  
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CORRELATIONS 
 
 TC TGL HDL LDL VLDL TC/HDL HDL/VLDL UA 
Pearson Correlation 1 .206(*) -.172 .884(**) .206(*) .664(**) -.241(*) .072 
Sig. (2-tailed)  .040 .087 .000 .040 .000 .016 .477 TC 
N 100 100 100 100 100 100 100 100 
Pearson Correlation .206(*) 1 -.137 -.223(*) 1.000(**) .223(*) -.697(**) .370(**) 
Sig. (2-tailed) .040  .174 .026 .000 .026 .000 .000 TGL 
N 100 100 100 100 100 100 100 100 
Pearson Correlation -.172 -.137 1 -.323(**) -.137 -.774(**) .786(**) -.038 
Sig. (2-tailed) .087 .174  .001 .174 .000 .000 .708 HDL 
N 100 100 100 100 100 100 100 100 
Pearson Correlation .884(**) -.223(*) -.323(**) 1 -.223(*) .695(**) -.090 -.090 
Sig. (2-tailed) .000 .026 .001  .026 .000 .371 .376 LDL 
N 100 100 100 100 100 100 100 100 
Pearson Correlation .206(*) 1.000(**) -.137 -.223(*) 1 .223(*) -.697(**) .370(**) 
Sig. (2-tailed) .040 .000 .174 .026  .026 .000 .000 VLDL 
N 100 100 100 100 100 100 100 100 
Pearson Correlation .664(**) .223(*) -.774(**) .695(**) .223(*) 1 -.664(**) .006 
Sig. (2-tailed) .000 .026 .000 .000 .026  .000 .949 TC/ HDL 
N 100 100 100 100 100 100 100 100 
Pearson Correlation -.241(*) -.697(**) .786(**) -.090 -.697(**) -.664(**) 1 -.277(**) 
Sig. (2-tailed) .016 .000 .000 .371 .000 .000  .005 HDL/VLDL 
N 100 100 100 100 100 100 100 100 
Pearson Correlation .072 .370(**) -.038 -.090 .370(**) .006 -.277(**) 1 
Sig. (2-tailed) .477 .000 .708 .376 .000 .949 .005   
UA 
  
  N 100 100 100 100 100 100 100 100 
*  Correlation is significant at the 0.05 level (2-tailed). 
**  Correlation is significant at the 0.01 level (2-tailed). 
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Correlations between the various lipid fractions in PIH Patients : 
 
1. There is significant positive correlation between Total Cholesterol and 
TGL, VLDL, LDL, TC/HDL ratio in pregnancy induced Hypertensive 
patients. 
 There is significant negative correlation between Total Cholesterol and 
HDL/VLDL ratio(i.e.) if Total cholesterol is increased in PIH the ratio of 
HDL /VLDL is decreased.  
2. The Triglyceride fraction is positively correlated with VLDL, Uric Acid & 
TC / HDL ratio and negatively correlated with HDL/VLDL ratio and both 
are highly significant.  
3. There is significant positive correlation between VLDL and TGL, UA, TC / 
HDL ratio which is highly significant. 
4. HDL fraction is positively correlated with HDL/VLDL ratio and negatively 
correlated with LDL and TC/HDL ratio and both are highly significant. 
 
 
 
 
 
 
 
 
 64
FACTOR ANALYSIS 
 
Rotated Component Matrix(a) 
 
Component 
 
1 2 3 
TC .085 .215 .963 
TGL .295 .928 -.050 
HDL -.949 .098 -.140 
LDL .159 -.235 .956 
VLDL .295 .928 -.050 
TC/HDL .751 .045 .627 
TGL/HDL .799 .556 .083 
HDL/VLDL -.841 -.498 -.065 
UA -.090 .615 .052 
 
Total Variance Explained  
 
 Rotation Sums of Squared Loadings 
Components 
Total % of Variance Cumulative % 
1 3.024 33.604 33.604 
2 2.771 30.791 64.396 
3 2.272 25.248 89.644 
 
1. TGL/HDL 
 
2. TGL or  VLDL 
 
3. TC 
 
The 3 factors accounted for 89.644 percent of the variance in the original 
nine variables. 
TGL/HDL, TGL or VLDL & TC contribute more to the Pregnancy induced 
Hypertension. 
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DISCUSSION 
There is dramatic alteration in lipid profile which has been elevated since 
20 weeks of gestation. 
 
From Table-1 we infer that total cholesterol is significantly elevated in 
women with Pregnancy Induced Hypertension when compared to normotensive 
pregnant women.  
 
Table-II shows the highly significant elevation of serum triglycerides in 
women with Pregnancy Induced Hypertensive than in normotensive pregnant 
women. 
 
Table-III shows the significant decrease in the serum level of  high density 
lipoprotein in women with Pregnancy Induced Hypertension when compared to 
normotensive pregnant women. 
 
Table-IV & V shows the highly significant elevation of low density 
lipoprotein and very low density lipoprotein respectively in women with 
Pregnancy Induced Hypertension. 
 
Pregnancy induced hypertension is a state of hypoestrogenemia(8,75). 
Decreased uteroplacental blood flow which is the main pathophysiological event in 
pregnancy induced hypertension leads to impairment in the formation of  
Dehydroepiandrosterone sulphate by fetal adrenal glands 
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1) DHEA.is the important source of estrogen in pregnancy,(i.e),90% of 
estrogen in maternal circulation is from fetal dehydroepiandrosterone sulphate 
which is converted to estriol in placenta.(93) Dehydroepiandrosteronesulphate on 
desulphuration and aromatisation by the enzymes sulphatase and aromatase in the 
placenta forms estriol.97 
 
                    Sulphatase                      
DHEAs estriol 
                     Aromatase 
Because of the impairment in the formation of dehydroepiandrosterone 
estrogen levels decrease. 
Uteroplacental perfusion  Lipid uptake by fetus  Synthesis of 
                                                                                                         DHEAs 
                                                                                                                
                                                                                              Estriol 
 
Moreover decrease in uteroplacental blood flow leads to relative stasis of maternal 
blood in the intervillous space resulting in redistribution of steroids formed in 
syncitium back to the fetus. 
Uteroplacental blood flow Relative stasis of maternal blood in the   
                                                       intervillous space 
  
                                                       Redistribution of steroids formed in syncitium 
                                                       back to the fetus instead of entering into 
                                                       maternal circulation. 
Hence a state of hypoestrogenemia develops.97 
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 69
         Since estrogen level is decreased after the placenta has taken over the 
function, there will be no decrease in the activities of lipoprotein lipase and hepatic 
lipase as in normal pregnancy,which is a state of hyperestrogenemia.This leads to 
increased levels of free fatty acids. 
 
          Free fatty acids are essential for the fetus for its energy needs. The very long 
chain fatty acids are synthesized by the fetal liver and brain from maternal linoleic 
and linolinic acids.  
 
           Further placental transport of fatty acids from maternal compartment is by 
simple diffusion but its capacity is limited. So for, lipid transfer across placenta 
fetus depends mainly upon VLDL/apo E receptors in the placenta. The expression 
of these receptors are increased by placental hormones but here in PIH,decreased 
estrogen leads to decreased expression of VLDL/apo E receptors resulting in 
reduced transport of VLDL to fetal compartment so there is maternal 
hypertriglycerimedia. 
 
Hypoestrogenemia         Decreased expression of VLDL /apoE receptors. 
 
                                          Decreased   transport of lipids to fetal compartment                 
 
                                         Increased maternal hypertriglyceridemia 
Further LDL taken up by the fetus for the synthesis of DHEA is decreased 
due to reduced fetoplacental perfusion leading to increased LDL.  
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Genetic Basis 
 
            Some studies show that mutation in LPL gene in pre-eclampsia may lead to 
lowered activity of LPL resulting in decreased hydrolysis of Triglycerides and 
predispose to dyslipidemia and cardiovascular disease91. 
 
            There are 3 common mutations in LPL gene,  
(1)  Asp9Asn substitution in exon 2,  
(2)  T-to-G substitution at position -93 of the proximal promotor region (-
93T/G), and  
(3)  Asn291Ser substitution in exon 6.  
 
             The LPL Asp9Asn mutation is in nonrandom association with a T-to-G    
substitution at position -93 of the proximal promotor region, and the combined -
93G/Asn9 genotype predisposes to decreased HDL cholesterol and an increased 
risk of coronary arterydisease.94. 
 
           Recently, a more common serine for asparagine substitution at residue 291 
(Asn291Ser) in exon 6 of the LPL gene has been described that is observed with 
high frequency, ranging from 2% to 5% in different populations.9 This common 
Asn291Ser LPL mutation significantly influences the risk for cardiovascular 
disease in patients with familialhypercholesterolemia95 
 
           There is also evidence that there is active role of placental LPL and Apo E 
in the metabolism of maternal lipoproteins and so fetal genes may modulate the 
risk for problems related to maternal dyslipidemia.96 
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            Genetic polymorphisms present in newborns are associatedwith variations 
of lipid concentrations in their mothers. 
 
1)  The presence of the S447X allele of LPL in newborns was associated with 
lower triglycerides, lower LDL-C, lower apoB, higher HDL-C, and higher 
apoA-I in their mothers, 
2)  The presence of the N291S allele of LPL in newborns was associated with 
higher triglycerides in their mothers. 
3)  The presence of the E2 allele of APOE in newborns was associated with 
higher LDL-C and apoB in their mothers.94 
 
In late gestation, high amounts of  TGs are found not only in VLDL but also 
in IDL, LDL, and HDL78,79. This is because of the reduced removal of lipoprotein 
TGs due to the decreased activities of lipoprotein lipase (LPL) and hepatic lipase 
(HL), the effect being more striking for HL than for LPL 80,81.  
 
Insufficient lipolysis of TG-rich lipoproteins leads to the accumulation of 
remnant lipoproteins, which are otherwise quickly removed from the circulation, 
with an increased TG content and prolonged residence time.  
 
The changes in lipoprotein metabolism observed in PIH closely resemble 
those seen in HL deficiency. 
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In the late phase of normal pregnancy, estrogen enhances the production of 
VLDLs and decreases maternal lipolytic activity80,81. Together with the increased 
expression of the VLDL/apoE receptors in the placenta82, this may result in a 
coordinated rerouting of TG-rich lipoproteins from the mother toward the 
fetoplacental unit to meet the nutritional demands of the growing fetus78. 
 
 But in pre-eclampsia, the reduced maternal lipolysis and the hampered 
uptake of TG-rich lipoproteins by the fetoplacental unit lead to the accumulation of 
TG-rich remnant lipoproteins in the maternal circulation  
 
           Remnant accumulation may reflect not only insufficient uptake of these 
particles by the fetoplacental unit but may also be pivotal to the development of 
clinical symptoms of pre-eclampsia. 
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Renal protein excretion and hypertension may both reflect endothelial 
dysfunction. Arbogast et al. (83) hypothesized that TG-rich lipoproteins from 
preeclamptic women damage the endothelium. Indeed, remnant lipoproteins are 
associated with impaired endothelial vasomotor function77, and earlier studies 
reported that women with PE have an increased pressure response to angiotensin 76 
In line with this, we observed an association of the accumulation of TGs in IDL 
particles and the depletion of dLDL particles, with diastolic blood pressure and of 
IDL triglycerides with proteinuria .This suggests that the alteration of the 
lipoprotein metabolism plays a key role in the development of the primary 
symptoms of PIH.  
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CONCLUSION 
 
There is a definite relationship between lipid profile and PIH. Moreover the 
hormonal imbalance is a prime factor for the aetiopathogenesis of PIH and this 
endocrinal imbalance is well reflected in alteration of serum lipid profile. Hence 
simple measurement of lipid profile at 20 weeks of gestation  can go a long way in 
prevention of the complications of PIH like, eclampsia, intrauterine growth 
retardation, HELLP syndrome future cardio vascular risk of the mother, future 
development of Hypertension and stroke. A clinical trial of life style and dietary 
modification would help.2,in cases of altered lipid metabolism. 
 
Further studies exploring the lipoprotein particles and microparticles as well 
as detailed analysis of microvascular bed of delivered placenta may address the 
role of lipid profile in the causation of  PIH. 
 
. Thus, our findings may be relevant for the future treatment by lipid 
modifying regimens of this life-threatening condition, for example, by drug 
therapy or lipoprotein apheresis 
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LIST OF ABBREVIATIONS 
AT1    - Angiotensin II TYPE 1 receptor  
ATP     - Adenosine Tri Phosphate 
CAMS    - Cellular Adhesion Molecules 
Enos    - Endothelial Nitric Oxide Synthase 
ET     - Endothelin 
FFA     - Free Fatty Acid 
GFR    - Glomerular Filtration Rate 
HDL     - High density lipoprotein 
HELLP   - Hemolysis, Elevated liver enzymes, Low  
platelet Syndrome 
ICAM -1   - Inter cellular Adhesion Molecule -1 
IUGR    - Intra Uterine Growth restriction 
LCAT    - Lecithin Cholesterol Acyl Transferase 
LDL    - Low density lipoprotein 
LPL    - Lipoprotein Lipase 
MMP2   - Matrix Metallo Proteinase 2 
NO    - Nitric Oxide 
PG12/TXA2   - Prostaglandin I2 / Thrombaxane A2 
P1GF    - Placental Growth Factor 
PIH    - Pregnancy induced hypertension 
RBF    - Renal Blood Flow 
ROS     - Reactive Oxygen Species 
sflt-1    - Soluble Fms like tyrosine Kinase -1 
TGL    - Triglycerides 
VEGF    - Vascular Endothelial Growth Factor 
VLDL    - Very low density lipoprotein 
VCAM -1   - Vascular  Cellular Adhesion Molecule-1 
FBS     - Fasting Blood Sugar 
UA     - Uric Acid  
